MedTrace Logo

Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI

NCT07231939 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 4000

Last updated 2025-11-17

No results posted yet for this study

Summary

All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion.

The final analysis will be limited to individuals in whom the volume of ICM administered during the index procedure was between 50 and 500 mL and for whom both pre- and post-procedure serum creatinine measurements were available.

The primary objective of the study is the effect of short-term and long-term SGLT2i therapy on the occurrence of CI-AKI in patients undergoing diagnostic or therapeutic procedures with ICM.

Conditions

Interventions

DRUG

Flozin

Patients who underwent percutaneous coronary interventions while using empagliflozin or dapagliflozin

Sponsors & Collaborators

  • Collegium Medicum w Bydgoszczy

    lead OTHER

Principal Investigators

  • Jacek Kubica, Prof. · Collegium Medicum w Bydgoszczy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2025-12-31
Completion
2026-03-31

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07231939 on ClinicalTrials.gov